73 related articles for article (PubMed ID: 19656202)
1. P-glycoprotein is not involved in the differential oral potency of naloxone and naltrexone.
Kanaan M; Daali Y; Dayer P; Desmeules J
Fundam Clin Pharmacol; 2009 Oct; 23(5):543-8. PubMed ID: 19656202
[TBL] [Abstract][Full Text] [Related]
2. Blood-brain barrier transport of naloxone does not involve P-glycoprotein-mediated efflux.
Suzuki T; Miyata M; Zaima C; Furuishi T; Fukami T; Kugawa F; Tomono K
J Pharm Sci; 2010 Jan; 99(1):413-21. PubMed ID: 19530072
[TBL] [Abstract][Full Text] [Related]
3. A combined cell based approach to identify P-glycoprotein substrates and inhibitors in a single assay.
Balimane PV; Chong S
Int J Pharm; 2005 Sep; 301(1-2):80-8. PubMed ID: 16023314
[TBL] [Abstract][Full Text] [Related]
4. Methadone inhibits rhodamine123 transport in Caco-2 cells.
Störmer E; Perloff MD; von Moltke LL; Greenblatt DJ
Drug Metab Dispos; 2001 Jul; 29(7):954-6. PubMed ID: 11408360
[TBL] [Abstract][Full Text] [Related]
5. Involvement of an influx transporter in the blood-brain barrier transport of naloxone.
Suzuki T; Ohmuro A; Miyata M; Furuishi T; Hidaka S; Kugawa F; Fukami T; Tomono K
Biopharm Drug Dispos; 2010 May; 31(4):243-52. PubMed ID: 20437463
[TBL] [Abstract][Full Text] [Related]
6. In-vitro respiratory drug absorption models possess nominal functional P-glycoprotein activity.
Madlova M; Bosquillon C; Asker D; Dolezal P; Forbes B
J Pharm Pharmacol; 2009 Mar; 61(3):293-301. PubMed ID: 19222901
[TBL] [Abstract][Full Text] [Related]
7. Contribution of P-glycoprotein to the enhancing effects of dimethyl-beta-cyclodextrin on oral bioavailability of tacrolimus.
Arima H; Yunomae K; Hirayama F; Uekama K
J Pharmacol Exp Ther; 2001 May; 297(2):547-55. PubMed ID: 11303042
[TBL] [Abstract][Full Text] [Related]
8. Comparison of drug efflux transport kinetics in various blood-brain barrier models.
Bachmeier CJ; Trickler WJ; Miller DW
Drug Metab Dispos; 2006 Jun; 34(6):998-1003. PubMed ID: 16554372
[TBL] [Abstract][Full Text] [Related]
9. Effects of capsaicin on P-gp function and expression in Caco-2 cells.
Han Y; Tan TM; Lim LY
Biochem Pharmacol; 2006 Jun; 71(12):1727-34. PubMed ID: 16674925
[TBL] [Abstract][Full Text] [Related]
10. Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein.
Bardelmeijer HA; Beijnen JH; Brouwer KR; Rosing H; Nooijen WJ; Schellens JH; van Tellingen O
Clin Cancer Res; 2000 Nov; 6(11):4416-21. PubMed ID: 11106262
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effect of fruit extracts on P-glycoprotein-related efflux carriers: an in-vitro screening.
Deferme S; Van Gelder J; Augustijns P
J Pharm Pharmacol; 2002 Sep; 54(9):1213-9. PubMed ID: 12356275
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic Interaction between Naloxone and Naltrexone Following Intranasal Administration to Healthy Subjects.
Krieter P; Chiang CN; Gyaw S; Skolnick P; Snyder R
Drug Metab Dispos; 2019 Jul; 47(7):690-698. PubMed ID: 30992306
[TBL] [Abstract][Full Text] [Related]
13. Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds.
Yumoto R; Murakami T; Nakamoto Y; Hasegawa R; Nagai J; Takano M
J Pharmacol Exp Ther; 1999 Apr; 289(1):149-55. PubMed ID: 10086998
[TBL] [Abstract][Full Text] [Related]
14. Effect of benzo[a]pyrene on P-glycoprotein-mediated transport in Caco-2 cell monolayer.
Sugihara N; Toyama K; Michihara A; Akasaki K; Tsuji H; Furuno K
Toxicology; 2006 Jun; 223(1-2):156-65. PubMed ID: 16647797
[TBL] [Abstract][Full Text] [Related]
15. Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro.
Wandel C; Kim RB; Guengerich FP; Wood AJ
Drug Metab Dispos; 2000 Aug; 28(8):895-8. PubMed ID: 10901697
[TBL] [Abstract][Full Text] [Related]
16. Echinacea purpurea and P-glycoprotein drug transport in Caco-2 cells.
Hansen TS; Nilsen OG
Phytother Res; 2009 Jan; 23(1):86-91. PubMed ID: 18688789
[TBL] [Abstract][Full Text] [Related]
17. The influence of enaminones on the transport and oral bioavailability of P-glycoprotein substrate therapeutic agents.
Salama NN; Scott KR; Eddington ND
Int J Pharm; 2004 Apr; 273(1-2):135-47. PubMed ID: 15010138
[TBL] [Abstract][Full Text] [Related]
18. Impact of P-glycoprotein on clopidogrel absorption.
Taubert D; von Beckerath N; Grimberg G; Lazar A; Jung N; Goeser T; Kastrati A; Schömig A; Schömig E
Clin Pharmacol Ther; 2006 Nov; 80(5):486-501. PubMed ID: 17112805
[TBL] [Abstract][Full Text] [Related]
19. Sirolimus and everolimus intestinal absorption and interaction with calcineurin inhibitors: a differential effect between cyclosporine and tacrolimus.
Lamoureux F; Picard N; Boussera B; Sauvage FL; Marquet P
Fundam Clin Pharmacol; 2012 Aug; 26(4):463-72. PubMed ID: 21631587
[TBL] [Abstract][Full Text] [Related]
20. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity.
Taub ME; Podila L; Ely D; Almeida I
Drug Metab Dispos; 2005 Nov; 33(11):1679-87. PubMed ID: 16093365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
